Harder 1994.

Methods	2‐week washout; 2‐week placebo run‐in period; inclusion criteria=sitting DBP 95‐115 mm Hg; 8‐week double‐blind treatment
Participants	All patients: n=16 (11 males, 5 females); all white; age range=42‐68 years; baseline SBP=163(23) mm Hg, DBP=103(8) mm Hg Bunazosin 3 mg: n=4; baseline supine SBP=155.3(23.9) mm Hg, DBP=100.0(7.1) mm Hg, HR=87.8(12.2) bpm Bunazosin 6 mg: n=4; baseline supine SBP=168.5(9.3) mm Hg, DBP=98.8(4.8) mm Hg; HR=76.0(13.5) bpm Bunazosin 12 mg: n=4; baseline supine SBP=180.3(28.4) mm Hg, DBP=110.0(8.6) mm Hg; HR=81.0(13.1) bpm Placebo: n=4; baseline supine SBP=149.0(21.0) mm Hg, DBP=102.5(6.5) mm Hg, HR=85.0(16.1) bpm
Interventions	Bunazosin 3 mg once daily Bunazosin 6 mg once daily Bunazosin 12 mg once daily Placebo
Outcomes	Trough supine SBP/DBP using mercury sphygmomanometer Trough supine HR WDAE
Notes	Individual patient BP and HR reported at baseline and endpoint; calculated BP change and SD of change for each group; BP and HR data from Table 1, p. 39
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Not described.
Allocation concealment (selection bias)	Unclear risk	Not described.
Blinding (performance bias and detection bias) All outcomes	Unclear risk	Not described.
Incomplete outcome data (attrition bias) All outcomes	Low risk	Quote: "One patient on 6 mg bunazosin was withdrawn from the study after the occurrence of nycturia due to mild heart failure."
Selective reporting (reporting bias)	Low risk	BP lowering efficacy was primary outcome. HR and safety/tolerability data reported.
Other bias	High risk	Quote: "The study was performed in one center as a part of a double‐blind, placebo controlled multicenter trial comparing the efficacy of three different dose levels of bunazosin and placebo in a parallel‐group design." Comment: Publication of the full trial results has not been identified. Risk of publication bias is high. Funding source not reported.